MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

Summary

To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.

Timeline

Start

2019-06-27

Primary completion

2020-02-06

Completion

2020-02-06

Drugs

Indications